Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Pelage Pharmaceuticals Closes $120M Series B Led by ARCH Venture Partners and GV
Series BVenture Capital

Pelage Pharmaceuticals Closes $120M Series B Led by ARCH Venture Partners and GV

•October 15, 2025
•Oct 15, 2025
0

Participants

Pelage

Pelage

company

ARCH Venture Partners

ARCH Venture Partners

investor

GV

GV

investor

Main Street Advisors

Main Street Advisors

investor

Visionary Ventures

Visionary Ventures

investor

Deal Summary

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotech based in Los Angeles, closed a $120M Series B financing co‑led by ARCH Venture Partners and GV, with participation from Main Street Advisors, Visionary Ventures and YK Bioventures. The company will use the funds to advance its clinical programs.

0

Comments

Want to join the conversation?

Loading comments...